Imugene Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Leslie Chong
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4-6 Bligh Street Sydney NSW Australia 2000
- IPO Date
- Jul 5, 2019
- Website
- imugene.com
- Similar Companies
- Business
- Imugene Limited (ASX: IMU; OTC: IUGNF) is a clinical-stage immuno-oncology company that develops innovative immunotherapies to activate the immune system of cancer patients against tumors. The company offers a diversified pipeline of product candidates, including the allogeneic CAR T-cell therapy azer-cel (azercabtagene zapreleucel), which targets CD19 for blood cancers such as diffuse large B-cell lymphoma; the oncolytic virotherapy platform CF33 (VAXINIA), including CF33-hNIS for imaging and CF33-CD19 (onCARlytics) to enhance CAR T responses in solid tumors; and B-cell immunotherapy vaccines such as HER-Vaxx, a HER2-positive vaccine for gastric and breast cancers, and PD1-Vaxx targeting the PD-1 checkpoint. These therapies aim to harness natural immune responses comparable to or exceeding monoclonal antibodies, often in combination with standard-of-care treatments, and target both hematological malignancies and solid tumors across patient populations with unmet needs. Founded in 1986 and headquartered in Sydney, Australia, Imugene conducts operations primarily in Australia and the United States through research facilities, clinical trial sites, and strategic partnerships. In April 2024, Imugene entered a strategic manufacturing and process development partnership with Kincell Bio, involving the sale of its North Carolina CGMP-compliant cell therapy facility for up to $6 million USD and the transfer of azer-cel activities, resulting in 50% staff reductions, $32 million USD in three-year cost savings, and an extended cash runway into 2026; the company also secured $37.5 million in funding for azer-cel advancement and received a $5.87 million R&D tax refund for fiscal 2024.
Figma shares rise as Bank of America resumes coverage with a ‘Buy’ rating
Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort
Shell flags 'significantly higher' gas trading and sells South Africa business - UPDATE
Imugene reports second BTKi cohort response - ICYMI
Imugene CEO details azer-cel trial milestone - ICYMI
Anthropic clears export hurdle for Fable 5, easing a threat to its IPO story
Imugene reports second complete response in azer-cel BTKi cohort
Fed may adopt leaner communications strategy under Warsh, says Deutsche Bank
Nasdaq leads Wall Street higher, Dow Jones notches new record as second quarter ends
Imugene reports first complete response in azer-cel BTKi cohort
FDA Fast Track opens new path for Imugene's Azer-cel - ICYMI
Inside Biotech: FDA fast-track nod sharpens focus on Imugene's off-the-shelf CAR T ambitions
Thor Energy lifted by hydrogen project update
Imugene showcases Azer-Cel progress at ASCO - ICYMI
Dow Jones, Nasdaq close at record levels as Trump says US-Iran peace talks are advancing
Costco's value strategy, membership growth support outlook after strong quarter, says Jefferies
Anthropic confidentially files to go public in the US
Iovance Biotherapeutics pushes cell therapy platform into solid tumor market
Small Cap Watch: commercial expansion updates drive news flow
Imugene presents azer-cel data at ASCO as trial expands into new cohort